Literature DB >> 19917836

Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials.

Suhail M Ali, Kim Leitzel, Allan Lipton, Walter P Carney, Wolfgang J Köstler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19917836     DOI： 10.1200/JCO.2009.23.4674

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  Challenges in the clinical utility of the serum test for HER2 ECD.

Authors:  Lian Lam; Nicholas McAndrew; Marla Yee; Ting Fu; Julia C Tchou; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2012-04-03

2.  Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.

Authors:  Xiying Shao; Xian Wang; Xiaohong Xu; Jianguo Feng; Mark Han; Han Zhang; Zhan-Hong Chen; Sheng Wang; Yi-Min Zang; Ping Huang; Hongchuan Jin; Xiaojia Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

3.  The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.

Authors:  Jung Sun Lee; Byung-Ho Son; Sei Hyun Ahn
Journal:  J Breast Cancer       Date:  2012-06-28       Impact factor: 3.588

Review 4.  Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?

Authors:  Walter P Carney; Dirk Bernhardt; Bharat Jasani
Journal:  Biomark Cancer       Date:  2013-08-12

Review 5.  Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.

Authors:  Hala Fawzy Mohamed Kamel; Hiba Saeed A Bagader Al-Amodi
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-08-13       Impact factor: 7.691

6.  An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.

Authors:  Alexandre Perrier; Pierre-Yves Boelle; Yves Chrétien; Joseph Gligorov; Jean-Pierre Lotz; Didier Brault; Eva Comperat; Guillaume Lefèvre; Mathieu Boissan
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

7.  Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.

Authors:  Serenella Eppenberger-Castori; Dirk Klingbiel; Thomas Ruhstaller; Daniel Dietrich; Daniel Alexander Rufle; Karin Rothgiesser; Olivia Pagani; Beat Thürlimann
Journal:  BMC Cancer       Date:  2020-02-11       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.